EnAoting Olanzapine and Fluoxetine Capsules

1. Indications and Usage
Bipolar I Depression: Indicated for the treatment of acute depressive episodes associated with Bipolar I Disorder.
2. Dosage and Administration
Recommended Dose: Administered once daily in the evening. The initial dose is typically 6 mg/25 mg (Olanzapine/Fluoxetine). The dose may be increased or decreased based on efficacy and tolerability within the range of 6 mg/25 mg to 12 mg/50 mg.
Administration: The capsules should be swallowed whole and can be taken with or without food.
Lithium or Anticonvulsants: If the patient is receiving lithium or anticonvulsants, dose titration should be performed with caution.
Missed Dose: If a dose is missed, it should not be replaced. Resume the normal dosing schedule at the next scheduled time.
3. Mechanism of Action
Olanzapine: A non-classical (atypical) antipsychotic agent that acts as an antagonist at multiple receptors, including serotonin 5-HT2A, dopamine D2, muscarinic, histaminergic, and alpha-1 adrenergic receptors.
Fluoxetine: A selective serotonin reuptake inhibitor (SSRI) that inhibits the reuptake of serotonin at the presynaptic neuronal membrane, thereby enhancing serotonergic neurotransmission.
4. Safety and Warnings
Suicidal Thoughts and Behaviors: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults.
Serotonin Syndrome: A potentially life-threatening condition that may occur, especially when used with other serotonergic drugs or MAOIs.
Metabolic Changes: Can cause hyperglycemia, dyslipidemia, and significant weight gain.
Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction characterized by hyperthermia, muscle rigidity, and altered mental status.
Tardive Dyskinesia: Potentially irreversible, involuntary movement disorder may occur with long-term use.
Cerebrovascular Adverse Events: Increased incidence in elderly patients with dementia-related psychotic conditions.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include somnolence, dry mouth, constipation, weight gain, dizziness, tremor, and akathisia.
Clinical Research: Clinical trials have demonstrated that the combination of olanzapine and fluoxetine is effective in reducing depressive symptoms in Bipolar I Disorder compared to placebo.
6. Drug Interactions
MAOIs: Contraindicated. A washout period of at least 14 days is required after stopping an MAOI, and at least 5 weeks after stopping olanzapine/fluoxetine before starting an MAOI.
CYP1A2 Inhibitors: Caffeine and theophylline metabolism may be inhibited.
CYP2D6 Substrates: Fluoxetine inhibits CYP2D6, potentially increasing plasma concentrations of drugs metabolized by this enzyme.
Other Serotonergic Drugs: Increased risk of serotonin syndrome.
7. Pharmaceutical Information
Composition: Each capsule contains varying ratios of olanzapine (3 mg, 6 mg, or 12 mg) and fluoxetine (as hydrochloride, 25 mg or 50 mg).
Appearance: Available as hard gelatin capsules.
Storage: Store at controlled room temperature (20°C to 25°C) in a tight container, protected from moisture and light.